| Outcome Measures: |
Primary: YG1699 concentration in plasma at different time, single-dose pharmacokinetic, 0 hour (h), 0.5h, 1h, 2h, 4h, 8h and 12h after the first dose of YG1699 (Day1); 24 hours after the first dose of YG1699 (Day2 morning) | Secondary: Metabolite 1 concentration in plasma at different time, single-dose pharmacokinetic, 0 hour (h), 0.5h, 1h, 2h, 4h, 8h and 12h after the first dose of YG1699 (Day1); 24 hours after the first dose of YG1699 (Day2 morning)|YG1699 steady-state concentration in plasma, steady-state pharmacokinetic, Day 9 morning（the first day after discontinuation of the drug）|Metabolite 1 steady-state concentration in plasma, steady-state pharmacokinetic, Day 9 morning（the first day after discontinuation of the drug）|Hemodialysis clearance of YG1699, pharmacokinetic, immediately before and immediately after the hemodialysis treatment on Day9|Hemodialysis clearance of Metabolite 1, pharmacokinetic, immediately before and immediately after the hemodialysis treatment on Day 9|OGTT, 0h, 1h, 2h, 3h blood glucose after taking 75g oral glucose, screen period and Day 8 (last day of medication)|24h urine glucose, screen period and Day 8 (last day of medication) | Other: Red blood cell count, Day9 morning（the first day after discontinuation of the drug）|White blood cell count, Day 9 morning（the first day after discontinuation of the drug）|Platelet count, Day 9 morning（the first day after discontinuation of the drug）|Hemoglobin, Day 9 morning（the first day after discontinuation of the drug）|Alanine aminotransaminase (ALT), Day 9 morning（the first day after discontinuation of the drug）|Aspartate aminotransferase (AST), Day 9 morning（the first day after discontinuation of the drug）|Total bilirubin, Day 9 morning（the first day after discontinuation of the drug）|Direct bilirubin, Day 9 morning（the first day after discontinuation of the drug）|Blood ketone body, Day 9 morning（the first day after discontinuation of the drug）|Blood pH, Day 9 morning（the first day after discontinuation of the drug）|Blood HCO3- concentration, Day 9 morning（the first day after discontinuation of the drug）|Serum creatinine, Day 9 morning（the first day after discontinuation of the drug）|estimated glomerular filtration rate (eGFR), Day 9 morning（the first day after discontinuation of the drug）|Urinary albumin/creatinine ratio (UACR), Day 9 morning（the first day after discontinuation of the drug）|ECG heart rate, Day 9 morning（the first day after discontinuation of the drug）|ECG heart rhythm, Day 9 morning（the first day after discontinuation of the drug）|ECG PR interval, Day 9 morning（the first day after discontinuation of the drug）|ECG QT interval, Day 9 morning（the first day after discontinuation of the drug）
|
